1. P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION. (23rd June 2022) Authors: Röth, A.; Egyed, M.; Ichikawa, S.; Ito, Y.; Kim, J. S.; Nagy, Z.; Obara, N.; Panse, J.; Schrezenmeier, H.; Sica, S.; Soret, J.; Usuki, K.; Yoon, S.-S.; Benkali, K.; Buri, M.; Lundberg, P.; Patel, H.; Shinomiya, K.; Sreckovic, S.; Nishimura, J.-I. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P831: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH CROVALIMAB: RESULTS FROM THE COMPOSER TRIAL. (23rd June 2022) Authors: Röth, A.; Panse, J.; Gentile, B.; Buri, M.; Patel, H.; Nagy, Z. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗